Put Options

4 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$0.82 - $1.42 $24,354 - $42,174
-29,700 Reduced 98.34%
500 $0
Q2 2023

Aug 14, 2023

BUY
$1.09 - $9.93 $30,847 - $281,019
28,300 Added 1489.47%
30,200 $36,000
Q1 2023

May 15, 2023

BUY
$7.77 - $12.47 $13,986 - $22,446
1,800 Added 1800.0%
1,900 $16,000
Q4 2022

Feb 14, 2023

BUY
$5.52 - $8.48 $552 - $848
100 New
100 $0

Others Institutions Holding RAIN

About Rain Therapeutics Inc.


  • Ticker RAIN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,837,400
  • Description
  • Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...
More about RAIN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.